No retraction, correction or concern found when last checked on Oct 18, 2026.

Unveiling the mechanisms and challenges of cancer drug resistance

Sameer Ullah Khan, Kaneez Fatima, Shariqa Aisha and 1 more

Cell Communication and Signaling · 2024 · Review · CC BY

doi:10.1186/s12964-023-01302-1

Read free

Abstract

Supplementary Information. The online version contains supplementary material available at 10.1186/s12964-023-01302-1.

References 400

1.
Nikolaou M, et al. The challenge of drug resistance in cancer treatment: a current overview. Clin Exp Metastasis. 2018;35(4):309-318.
Not in our library10.1007/s10585-018-9903-0
2.
Saha M, Sarkar A. Review on Multiple Facets of Drug Resistance: A Rising Challenge in the 21st Century. J Xenobiot. 2021;11(4):197-214.
Not in our library10.3390/jox11040013
3.
Boumahdi S, de Sauvage FJ. The great escape: tumour cell plasticity in resistance to targeted therapy. Nat Rev Drug Discov. 2020;19(1):39-56.
Not in our library10.1038/s41573-019-0044-1
4.
Michaelis M, Wass MN, Cinatl J. Drug-adapted cancer cell lines as preclinical models of acquired resistance. Cancer Drug Resist. 2019;2(3):447-456.
Not in our library10.20517/cdr.2019.005
5.
Oun R, Moussa YE, Wheate NJ. The side effects of platinum-based chemotherapy drugs: a review for chemists. Dalton Trans. 2018;47(19):6645-6653.
Not in our library10.1039/c8dt00838h
6.
Tao JJ, Visvanathan K, Wolff AC. Long term side effects of adjuvant chemotherapy in patients with early breast cancer. Breast. 2015;24:S149-S153.
Not in our library10.1016/j.breast.2015.07.035
7.
Aramini B, et al. Dissecting tumor growth: The role of cancer stem cells in drug resistance and recurrence. Cancers (Basel). 2022;14(4):976.
Not in our library10.3390/cancers14040976
8.
Masoudi M, Gopalan V. Roles of Cancer Stem Cells in Therapy Resistance and Disease Recurrence. Cancer Stem Cells: Basic Concept and Therapeutic Implications. 2023;149-165.
Not in our library
9.
Overcoming cancer therapeutic bottleneck by drug repurposing · 2020
No notice
10.
DeRidder L, et al. The past, present, and future of chemotherapy with a focus on individualization of drug dosing. J Control Release. 2022;352:840-860.
Not in our library10.1016/j.jconrel.2022.10.043
11.
Targeting strategies for bone diseases: signaling pathways and clinical studies · 2023
No notice
12.
Miglietta F, et al. Endocrine sequelae of hematopoietic stem cell transplantation: Effects on mineral homeostasis and bone metabolism. Front Endocrinol (Lausanne). 2023;13:1085315.
Not in our library10.3389/fendo.2022.1085315
13.
The Different Mechanisms of Cancer Drug Resistance: A Brief Review · 2017
No notice
14.
Drug resistance and combating drug resistance in cancer · 2019
No notice
15.
Dzobo K, et al. Not Everyone Fits the Mold: Intratumor and Intertumor Heterogeneity and Innovative Cancer Drug Design and Development. OMICS. 2018;22(1):17-34.
Not in our library10.1089/omi.2017.0174
16.
Labrie M, et al. Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer. Nat Rev Cancer. 2022;22(6):323-339.
Not in our library10.1038/s41568-022-00454-5
17.
Nussinov R, Tsai CJ, Jang H. Anticancer drug resistance: An update and perspective. Drug Resist Updat. 2021;59:100796.
Not in our library10.1016/j.drup.2021.100796
18.
The Tumor Microenvironment in Tumorigenesis and Therapy Resistance Revisited · 2023
No notice
19.
Dzobo K, et al. Advances in Therapeutic Targeting of Cancer Stem Cells within the Tumor Microenvironment: An Updated Review. Cells. 2020;9(8):1896.
Not in our library10.3390/cells9081896
20.
The Role of Tumor Microenvironment in Chemoresistance: To Survive, Keep Your Enemies Closer · 2017
No notice
21.
Khan SU, Fatima K, Malik F, Kalkavan H, Wani A. Cancer metastasis: Molecular mechanisms and clinical perspectives. Pharmacol Ther. 2023;250:108522..
Not in our library10.1016/j.pharmthera.2023.108522
22.
Yang Q, et al. Extracellular Vesicles in Cancer Drug Resistance: Roles, Mechanisms, and Implications. Adv Sci (Weinh). 2022;9(34):e2201609.
Not in our library10.1002/advs.202201609
23.
Namee NM, O'Driscoll L. Extracellular vesicles and anti-cancer drug resistance. Biochim Biophys Acta Rev Cancer. 2018;1870(2):123-136.
Not in our library10.1016/j.bbcan.2018.07.003
24.
Wu S. Fu L, Tyrosine kinase inhibitors enhanced the efficacy of conventional chemotherapeutic agent in multidrug resistant cancer cells. Mol Cancer. 2018;17(1):1-13.
Not in our library10.1186/s12943-018-0775-3
25.
Roviello G, et al. Apatinib: a novel receptor tyrosine kinase inhibitor for the treatment of gastric cancer. Cancer Lett. 2016;372(2):187-191.
Not in our library10.1016/j.canlet.2016.01.014
26.
Martin SK, et al. N-terminal targeting of androgen receptor variant enhances response of castration resistant prostate cancer to taxane chemotherapy. Mol Oncol. 2015;9(3):628-639.
Not in our library10.1016/j.molonc.2014.10.014
27.
Fujita K, Nonomura N. Role of androgen receptor in prostate cancer: a review. World J Mens Health. 2019;37(3):288-295.
Not in our library10.5534/wjmh.180040
28.
Asano Y, et al. Clinical verification of sensitivity to preoperative chemotherapy in cases of androgen receptor-expressing positive breast cancer. Br J Cancer. 2016;114(1):14-20.
Not in our library10.1038/bjc.2015.434
29.
Barton VN, et al. Androgen receptor supports an anchorage-independent, cancer stem cell-like population in triple-negative breast cancer. Cancer Res. 2017;77(13):3455-3466.
Not in our library10.1158/0008-5472.can-16-3240
30.
Niikura N, et al. Changes in tumor expression of HER2 and hormone receptors status after neoadjuvant chemotherapy in 21 755 patients from the Japanese breast cancer registry. Ann Oncol. 2016;27(3):480-487.
Not in our library10.1093/annonc/mdv611
31.
Tolaney SM, et al. Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial. Lancet Oncol. 2020;21(6):763-775.
Not in our library10.1016/s1470-2045(20)30112-1
32.
Calabrò L, et al. Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study. Lancet Respir Med. 2015;3(4):301-309.
Not in our library10.1016/s2213-2600(15)00092-2
33.
Calabrò L, et al. Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial. Lancet Oncol. 2013;14(11):1104-1111.
Not in our library10.1016/s1470-2045(13)70381-4
34.
Noguchi T, et al. Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune EscapeThe Role of Tumor versus Host PD-L1 in Tumor Immune Escape. Cancer Immunol Res. 2017;5(2):106-117.
Not in our library10.1158/2326-6066.cir-16-0391
35.
Juneja VR, et al. PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity. J Exp Med. 2017;214(4):895-904.
Not in our library10.1084/jem.20160801
36.
Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350-1355.
Not in our library10.1126/science.aar4060
37.
Tumor cell plasticity in targeted therapy-induced resistance: mechanisms and new strategies · 2023
No notice
38.
Prasad B, et al. Exploration of space to achieve scientific breakthroughs. Biotechnol Adv. 2020;43:107572.
Not in our library10.1016/j.biotechadv.2020.107572
39.
Jin H, Wang L, Bernards R. Rational combinations of targeted cancer therapies: background, advances and challenges. Nat Rev Drug Discovery. 2023;22(3):213-234.
Not in our library10.1038/s41573-022-00615-z
40.
Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy · 2019
No notice
41.
Krook MA, et al. Tumor heterogeneity and acquired drug resistance in FGFR2-fusion-positive cholangiocarcinoma through rapid research autopsy. Cold Spring Harb Mol Case Stud. 2019;5(4):a004002.
Not in our library10.1101/mcs.a004002
42.
Guillon J, et al. Chemotherapy-induced senescence, an adaptive mechanism driving resistance and tumor heterogeneity. Cell Cycle. 2019;18(19):2385-2397.
Not in our library10.1080/15384101.2019.1652047
43.
Impact of the Tumor Microenvironment on Tumor Heterogeneity and Consequences for Cancer Cell Plasticity and Stemness · 2020
No notice
44.
Punter KB, Chu CE, Chan YW. Mitochondrial dynamics and oxidative phosphorylation as critical targets in cancer. Endocr Relat Cancer. 2023;30(1):e220229.
Not in our library10.1530/erc-22-0229
45.
Hanselmann RG, Welter C. Origin of Cancer: Cell work is the Key to Understanding Cancer Initiation and Progression. Front Cell Dev Biol. 2022;10:787995. 10.3389/fcell.2022.787995.
Not in our library10.3389/fcell.2022.787995
46.
Jiang W, et al. Personalized medicine of non-gene-specific chemotherapies for non-small cell lung cancer. Acta Pharm Sin B. 2021;11(11):3406-3416.
Not in our library10.1016/j.apsb.2021.02.003
47.
Capdevila J, et al. Molecular diagnosis and targeted treatment of advanced follicular cell-derived thyroid cancer in the precision medicine era. Cancer Treat Rev. 2022;106:102380.
Not in our library10.1016/j.ctrv.2022.102380
48.
Bhang H-e C, et al. Studying clonal dynamics in response to cancer therapy using high-complexity barcoding. Nat Med. 2015;21(5):440-448.
Not in our library10.1038/nm.3841
49.
Jamal-Hanjani M, et al. Tracking the evolution of non–small-cell lung cancer. N Engl J Med. 2017;376(22):2109-2121.
Not in our library10.1056/nejmoa1616288
50.
Singh AK, et al. Tumor heterogeneity and cancer stem cell paradigm: updates in concept, controversies and clinical relevance. Int J Cancer. 2015;136(9):1991-2000.
Not in our library10.1002/ijc.28804
51.
DNA damage repair: historical perspectives, mechanistic pathways and clinical translation for targeted cancer therapy · 2021
No notice
52.
Roberts SA, Gordenin DA. Hypermutation in human cancer genomes: footprints and mechanisms. Nat Rev Cancer. 2014;14(12):786-800.
Not in our library10.1038/nrc3816
53.
Khan SU, et al. Redox balance and autophagy regulation in cancer progression and their therapeutic perspective. Med Oncol. 2023;40(1):1-21.
Not in our library10.1007/s12032-022-01871-0
54.
Sui Q, et al. Genetic and microenvironmental differences in non-smoking lung adenocarcinoma patients compared with smoking patients. Transl Lung Cancer Res. 2020;9(4):1407.
Not in our library10.21037/tlcr-20-276
55.
Anagnostou V, et al. Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer. Nat Cancer. 2020;1(1):99-111.
Not in our library10.1038/s43018-019-0008-8
56.
Connor AA. Gallinger S, Pancreatic cancer evolution and heterogeneity: integrating omics and clinical data. Nat Rev Cancer. 2022;22(3):131-142.
Not in our library10.1038/s41568-021-00418-1
57.
Killcoyne S, Fitzgerald RC. Evolution and progression of Barrett’s oesophagus to oesophageal cancer. Nat Rev Cancer. 2021;21(11):731-741.
Not in our library10.1038/s41568-021-00400-x
58.
Sjödahl G, et al. Molecular changes during progression from nonmuscle invasive to advanced urothelial carcinoma. Int J Cancer. 2020;146(9):2636-2647.
Not in our library10.1002/ijc.32737
59.
van Niekerk G, et al. C ancer stem cells: A product of clonal evolution? Int J Cancer. 2017;140(5):993-999.
Not in our library10.1002/ijc.30448
60.
Intratumoral heterogeneity and clonal evolution in liver cancer · 2020
No notice
61.
Zardavas D, et al. Clinical management of breast cancer heterogeneity. Nat Rev Clin Oncol. 2015;12(7):381-394.
Not in our library10.1038/nrclinonc.2015.73
62.
Al-Rawi DH, Bakhoum SF. Chromosomal instability as a source of genomic plasticity. Curr Opin Genet Dev. 2022;74:101913.
Not in our library10.1016/j.gde.2022.101913
63.
van den Bosch T, Derks S, Miedema DMJC. Chromosomal Instability Selection and Competition: Factors That Shape the Level of Karyotype Intra-Tumor Heterogeneity. Cancers (Basel). 2022;14(20):4986.
Not in our library10.3390/cancers14204986
64.
Comaills V, Castellano-Pozo MJB. Chromosomal Instability in Genome Evolution: From Cancer to Macroevolution. Biology (Basel). 2023;12(5):671.
Not in our library10.3390/biology12050671
65.
Majc B, et al. Epithelial-to-mesenchymal transition as the driver of changing carcinoma and glioblastoma microenvironment. Biochim Biophys Acta Mol Cell Res. 2020;1867(10):118782.
Not in our library10.1016/j.bbamcr.2020.118782
66.
Levitin HM, Yuan J, Sims PA. Single-cell transcriptomic analysis of tumor heterogeneity. Trends Cancer. 2018;4(4):264-268.
Not in our library10.1016/j.trecan.2018.02.003
67.
Fan J, et al. Linking transcriptional and genetic tumor heterogeneity through allele analysis of single-cell RNA-seq data. Genome Res. 2018;28(8):1217-1227.
Not in our library10.1101/gr.228080.117
68.
Peng J, et al. Single-cell RNA-seq highlights intra-tumoral heterogeneity and malignant progression in pancreatic ductal adenocarcinoma. Cell Res. 2019;29(9):725-738.
Not in our library10.1038/s41422-019-0195-y
69.
Ding S, Chen X, Shen KJCC. Single-cell RNA sequencing in breast cancer: Understanding tumor heterogeneity and paving roads to individualized therapy. Cancer Commun (Lond). 2020;40(8):329-344.
Not in our library10.1002/cac2.12078
70.
Hata AN, et al. Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition. Nat Med. 2016;22(3):262-269.
Not in our library10.1038/nm.4040
71.
Single-cell RNA sequencing shows the immunosuppressive landscape and tumor heterogeneity of HBV-associated hepatocellular carcinoma · 2021
No notice
72.
Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials · 2019
No notice
73.
Mancarella D, Plass C. Epigenetic signatures in cancer: proper controls, current challenges and the potential for clinical translation. Genome Med. 2021;13:1-12.
Not in our library10.1186/s13073-021-00837-7
74.
Mikubo M, et al. Mechanism of drug tolerant persister cancer cells: the landscape and clinical implication for therapy. J Thorac Oncol. 2021;16(11):1798-1809.
Not in our library10.1016/j.jtho.2021.07.017
75.
De Conti G, Dias MH, Bernards RJC. Fighting drug resistance through the targeting of drug-tolerant persister cells. Cancers (Basel). 2021;13(5):1118.
Not in our library10.3390/cancers13051118
76.
Epigenetics in cancer stem cells · 2017
No notice
77.
Fouad MA, et al. Impact of global DNA methylation in treatment outcome of colorectal cancer patients. Front Pharmacol. 2018;9:1173.
Not in our library10.3389/fphar.2018.01173
78.
Lee DD, et al. DNA methylation of the TERT promoter and its impact on human cancer. Curr Opin Genet Dev. 2020;60:17-24.
Not in our library10.1016/j.gde.2020.02.003
79.
Wu Q, et al. Methylation of miR-129-5p CpG island modulates multi-drug resistance in gastric cancer by targeting ABC transporters. Oncotarget. 2014;5(22):11552-11563.
Not in our library10.18632/oncotarget.2594
80.
The Role of Tumor-Stroma Interactions in Drug Resistance Within Tumor Microenvironment · 2021
No notice
81.
Genome-wide DNA methylation analysis of breast cancer MCF-7 / Taxol cells with MeDIP-Seq. · 2020
Not checked
82.
Aguiari G, et al. Dysregulation of Transglutaminase type 2 through GATA3 defines aggressiveness and Doxorubicin sensitivity in breast cancer. Int J Biol Sci. 2022;18(1):1.
Not in our library10.7150/ijbs.64167
83.
Mosca L, et al. Therapeutic potential of the natural compound S-adenosylmethionine as a chemoprotective synergistic agent in breast, and head and neck cancer treatment: Current status of research. Int J Mol Sci. 2020;21(22):8547.
Not in our library10.3390/ijms21228547
84.
Williams MM, Cook RS. Bcl-2 family proteins in breast development and cancer: could Mcl-1 targeting overcome therapeutic resistance? Oncotarget. 2015;6(6):3519.
Not in our library10.18632/oncotarget.2792
85.
Baharudin R, et al. Identification of predictive DNA methylation biomarkers for chemotherapy response in colorectal cancer. Front Pharmacol. 2017;8:47.
Not in our library10.3389/fphar.2017.00047
86.
Histone methyltransferase and drug resistance in cancers · 2020
Not checked
87.
Liu C-W, et al. Histone Methyltransferase G9a Drives Chemotherapy Resistance by Regulating the Glutamate-Cysteine Ligase Catalytic Subunit in Head and Neck Squamous Cell CarcinomaG9a Modulates GCLC Expression and Chemoresistance. Mol Cancer Ther. 2017;16(7):1421-1434.
Not in our library10.1158/1535-7163.mct-16-0567-t
88.
Musiani D, et al. PRMT1 Is Recruited via DNA-PK to Chromatin Where It Sustains the Senescence-Associated Secretory Phenotype in Response to Cisplatin. Cell Rep. 2020;30(4):1208-1222.e9.
Not in our library10.1016/j.celrep.2019.12.061
89.
Cancer Stem Cells—Origins and Biomarkers: Perspectives for Targeted Personalized Therapies · 2020
No notice
90.
Trumpp A, Haas SJC. Cancer stem cells: the adventurous journey from hematopoietic to leukemic stem cells. Cells. 2022;185(8):1266-1270.
Not in our library10.1016/j.cell.2022.03.025
91.
Kapoor-Narula U, Lenka NJC. Cancer stem cells and tumor heterogeneity: Deciphering the role in tumor progression and metastasis. Cytokine. 2022;157:155968.
Not in our library10.1016/j.cyto.2022.155968
92.
Breast Cancer Stem Cells as Drivers of Tumor Chemoresistance, Dormancy and Relapse: New Challenges and Therapeutic Opportunities · 2019
No notice
93.
Paul R, et al. Cell plasticity, senescence, and quiescence in cancer stem cells: Biological and therapeutic implications. Pharmacol Ther. 2022;231:107985.
Not in our library10.1016/j.pharmthera.2021.107985
94.
Tang H, et al. miR-200c suppresses stemness and increases cellular sensitivity to trastuzumab in HER2+ breast cancer. J Cell Mol Med. 2019;23(12):8114-8127.
Not in our library10.1111/jcmm.14681
95.
Dittmer A, Dittmer JJC. Carcinoma-associated fibroblasts promote growth of Sox2-expressing breast cancer cells. Cancers (Basel). 2020;12(11):3435.
Not in our library10.3390/cancers12113435
96.
Giuli MV, et al. Notch signaling in female cancers: A multifaceted node to overcome drug resistance. Cancer Drug Resist. 2021;4(4):805.
Not in our library10.20517/cdr.2021.53
97.
Mourkioti I, et al. Interplay of Developmental Hippo-Notch Signaling Pathways with the DNA Damage Response in Prostate Cancer. Cells. 2022;11(15):2449.
Not in our library10.3390/cells11152449
98.
Aggarwal V, et al. NOTCH signaling: Journey of an evolutionarily conserved pathway in driving tumor progression and its modulation as a therapeutic target. Crit Rev Oncol Hematol. 2021;164:103403.
Not in our library10.1016/j.critrevonc.2021.103403
99.
Yan Q, et al. Oncofetal proteins and cancer stem cells. 2022.
Not in our library10.1042/ebc20220025
100.
Sun D, et al. The IVF-generated human embryonic microenvironment reverses progestin resistance in endometrial cancer cells by inducing cancer stem cell differentiation. Cancer Lett. 2022;526:311-321.
Not in our library10.1016/j.canlet.2021.11.003
101.
Emerging agents that target signaling pathways in cancer stem cells · 2020
No notice
102.
Cheng S-W, et al. Lin28B is an oncofetal circulating cancer stem cell-like marker associated with recurrence of hepatocellular carcinoma. PLoS ONE. 2013;8(11):e80053.
Not in our library10.1371/journal.pone.0080053
103.
Karsten U, Goletz S. What makes cancer stem cell markers different? Springerplus. 2013;2(1):1-8.
Not in our library10.1186/2193-1801-2-301
104.
Liu L, et al. Chemotherapy Induces Breast Cancer Stemness in Association with Dysregulated MonocytosisMCPs Mediate Chemotherapy-Induced Cancer Stemness. Clin Cancer Res. 2018;24(10):2370-2382.
Not in our library10.1158/1078-0432.ccr-17-2545
105.
Alhaddad L, Osipov AN, Leonov S. The Molecular and Cellular Strategies of Glioblastoma and Non-Small-Cell Lung Cancer Cells Conferring Radioresistance. Int J Mol Sci. 2022;23(21):13577.
Not in our library10.3390/ijms232113577
106.
Bazan, N.G., et al., Multiprong control of glioblastoma multiforme invasiveness: blockade of pro-inflammatory signaling, anti-angiogenesis, and homeostasis restoration. 2021: p. 1–5.
Not in our library10.1007/s10555-021-09987-x
107.
Angom RS, Mondal SK, Wang F, Madamsetty VS, Wang E, Dutta SK, Gulani Y, Sarabia-Estrada R, Sarkaria JN, Quiñones-Hinojosa A, Mukhopadhyay D. Ablation of neuropilin-1 improves the therapeutic response in conventional drug-resistant glioblastoma multiforme. Oncogene. 2020;39(48):7114-7126.
Not in our library10.1038/s41388-020-01462-1
108.
Bazan NG, Reid MM, Flores VAC, Gallo JE, Lewis W, Belayev L. Multiprong control of glioblastoma multiforme invasiveness: blockade of pro-inflammatory signaling, anti-angiogenesis, and homeostasis restoration. Cancer Metastasis Rev. 2021;40(3):643-647.
Not in our library10.1007/s10555-021-09987-x
109.
Neuropilin-1: A Key Protein to Consider in the Progression of Pediatric Brain Tumors · 2021
Not checked
110.
Zhang Q, et al. miR34a/GOLPH3 axis abrogates urothelial bladder cancer chemoresistance via reduced cancer stemness. Theranostics. 2017;7(19):4777.
Not in our library10.7150/thno.21713
111.
Allegra A, et al. The cancer stem cell hypothesis: a guide to potential molecular targets. Cancer Invest. 2014;32(9):470-495.
Not in our library10.3109/07357907.2014.958231
112.
Castelli V, et al. The great escape: the power of cancer stem cells to evade programmed cell death. Cancers (Basel). 2021;13(2):328.
Not in our library10.3390/cancers13020328
113.
Pan E, et al. Phase I study of RO4929097 with bevacizumab in patients with recurrent malignant glioma. J Neurooncol. 2016;130:571-579.
Not in our library10.1007/s11060-016-2263-1
114.
Villalobos VM, et al. Long-term follow-up of desmoid fibromatosis treated with PF-03084014, an oral gamma secretase inhibitor. Ann Surg Oncol. 2018;25:768-775.
Not in our library10.1245/s10434-017-6082-1
115.
Safety, Tolerability, and Preliminary Efficacy of the Anti-Fibrotic Small Molecule PRI-724, a CBP/β-Catenin Inhibitor, in Patients with Hepatitis C Virus-related Cirrhosis: A Single-Center, Open-Label, Dose Escalation Phase 1 Trial · 2017
Not checked
116.
Dréno B, et al. Two intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas (MIKIE): a randomised, regimen-controlled, double-blind, phase 2 trial. Lancet Oncol. 2017;18(3):404-412.
Not in our library10.1016/s1470-2045(17)30072-4
117.
Shibue T, Weinberg RA. EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. Nat Rev Clin Oncol. 2017;14(10):611-629.
Not in our library10.1038/nrclinonc.2017.44
118.
Khan SU, Fatima K, Malik F. Understanding the cell survival mechanism of anoikis-resistant cancer cells during different steps of metastasis. Clin Exp Metastasis. 2022;39(5):715-726.
Not in our library10.1007/s10585-022-10172-9
119.
Targeting Cancer Stem Cells: A Strategy for Effective Eradication of Cancer · 2019
No notice
120.
ABC transporters in CSCs membranes as a novel target for treating tumour relapse · 2014
Not checked
121.
Zhao Y, et al. Eradication of cancer stem cells in triple negative breast cancer using doxorubicin/pluronic polymeric micelles. Nanomedicine. 2020;24:102124.
Not in our library10.1016/j.nano.2019.102124
122.
Kim EJ, et al. NRF2 knockdown resensitizes 5-fluorouracil-resistant pancreatic cancer cells by suppressing HO-1 and ABCG2 expression. Int J Mol Sci. 2020;21(13):4646.
Not in our library10.3390/ijms21134646
123.
Eldaly, S.M., S.A. Gouhar, and M.T.J.E.J.o.C. Abo-elfadl, The Influence of 5-Fluorouracil on Drug Transporters is a Dose-Dependent Effect Mediated by Altered Expression of miRNAs. 2022. 65(8): p. 737–748.
Not in our library
124.
Kukal S, Guin D, Rawat C, Bora S, Mishra MK, Sharma P, Paul PR, Kanojia N, Grewal GK, Kukreti S, Saso L, Kukreti R. Multidrug efflux transporter ABCG2: expression and regulation. Cell Mol Life Sci. 2021;78(21–22):6887-6939.
Not in our library10.1007/s00018-021-03901-y
125.
Hsu HH, Chen MC, Baskaran R, Lin YM, Day CH, Lin YJ, Tu CC, Vijaya Padma V, Kuo WW, Huang CY. Oxaliplatin resistance in colorectal cancer cells is mediated via activation of ABCG2 to alleviate ER stress induced apoptosis. J Cell Physiol. 2018;233(7):5458-5467.
Not in our library10.1002/jcp.26406
126.
Ravindranath AK, et al. CD44 promotes multi-drug resistance by protecting P-glycoprotein from FBXO21-mediated ubiquitination. Oncotarget. 2015;6(28):26308.
Not in our library10.18632/oncotarget.4763
127.
Zhang H, et al. Cancer stem cells, epithelial-mesenchymal transition, ATP and their roles in drug resistance in cancer. Cancer Drug Resist. 2021;4(3):684.
Not in our library10.20517/cdr.2021.32
128.
Lv Y, et al. Hypoxia-inducible factor-1α induces multidrug resistance protein in colon cancer. Onco Targets Ther. 2015;8:1941.
Not in our library10.2147/ott.s82835
129.
Mechanisms of Chemotherapy Resistance in Triple-Negative Breast Cancer—How We Can Rise to the Challenge · 2019
No notice
130.
The hypoxic tumor microenvironment in vivo selects the cancer stem cell fate of breast cancer cells · 2018
Not checked
131.
Role of hypoxia in cancer therapy by regulating the tumor microenvironment · 2019
No notice
132.
Khan, S.U., K. Fatima, and F. Malik, Understanding the cell survival mechanism of anoikis-resistant cancer cells during different steps of metastasis. Clin Exp Metastasis, 2022.
Not in our library10.1007/s10585-022-10172-9
133.
Activation of lysosomal mediated cell death in the course of autophagy by mTORC1 inhibitor · 2022
Not checked
134.
Wani A, et al. Crocetin promotes clearance of amyloid-β by inducing autophagy via the STK11/LKB1-mediated AMPK pathway. Autophagy. 2021;17(11):3813-3832.
Not in our library10.1080/15548627.2021.1872187
135.
Han Y, et al. Role of autophagy in breast cancer and breast cancer stem cells. Int J Oncol. 2018;52(4):1057-1070.
Not in our library10.3892/ijo.2018.4270
136.
Gong C, et al. Beclin 1 and autophagy are required for the tumorigenicity of breast cancer stem-like/progenitor cells. Oncogene. 2013;32(18):2261-2272.
Not in our library10.1038/onc.2012.252
137.
Autophagy inhibition reduces chemoresistance and tumorigenic potential of human ovarian cancer stem cells · 2017
No notice
138.
Liu W, et al. PRDX1 activates autophagy via the PTEN-AKT signaling pathway to protect against cisplatin-induced spiral ganglion neuron damage. Autophagy. 2021;17(12):4159-4181.
Not in our library10.1080/15548627.2021.1905466
139.
Khan SU, Rayees S, Sharma P, Malik F. Targeting redox regulation and autophagy systems in cancer stem cells. Clin Exp Med. 2023;23(5):1405-1423.
Not in our library10.1007/s10238-022-00955-5
140.
Raha D, et al. The Cancer Stem Cell Marker Aldehyde Dehydrogenase Is Required to Maintain a Drug-Tolerant Tumor Cell SubpopulationAldehyde Dehydrogenase Contributes to Cancer Drug Resistance. Cancer Res. 2014;74(13):3579-3590.
Not in our library10.1158/0008-5472.can-13-3456
141.
Wu W, et al. Aldehyde dehydrogenase 1A3 (ALDH1A3) is regulated by autophagy in human glioblastoma cells. Cancer Lett. 2018;417:112-123.
Not in our library10.1016/j.canlet.2017.12.036
142.
Yeo SK, et al. Autophagy Differentially Regulates Distinct Breast Cancer Stem-like Cells in Murine Models via EGFR/Stat3 and Tgfβ/Smad SignalingRegulation of Distinct Breast Cancer Stem Cells by Autophagy. Cancer Res. 2016;76(11):3397-3410.
Not in our library10.1158/0008-5472.can-15-2946
143.
Shih P-C, Mei K. Role of STAT3 signaling transduction pathways in cancer stem cell-associated chemoresistance. Drug Discov Today. 2021;26(6):1450-1458.
Not in our library10.1016/j.drudis.2020.11.032
144.
Jin, M L, Jeong K W, Histone modifications in drug-resistant cancers: From a cancer stem cell and immune evasion perspective. 2023: 1–15.
Not in our library10.1038/s12276-023-01014-z
145.
Zeng F, et al. Comprehensive profiling identifies a novel signature with robust predictive value and reveals the potential drug resistance mechanism in glioma. Cell Commun Signal. 2020;18:1-13.
Not in our library10.1186/s12964-019-0492-6
146.
Chung AW, et al. Tocilizumab overcomes chemotherapy resistance in mesenchymal stem-like breast cancer by negating autocrine IL-1A induction of IL-6. NPJ Breast Cancer. 2022;8(1):1-10.
Not in our library10.1038/s41523-021-00371-0
147.
Dianat-Moghadam H, et al. Cancer stem cells-emanated therapy resistance: implications for liposomal drug delivery systems. J Control Release. 2018;288:62-83.
Not in our library10.1016/j.jconrel.2018.08.043
148.
Codony-Servat J, Rosell R. Cancer stem cells and immunoresistance: clinical implications and solutions. Transl Lung Cancer Res. 2015;4(6):689-703.
Not in our library10.3978/j.issn.2218-6751.2015.12.11
149.
Najafi M. Mortezaee K, Majidpoor J, Cancer stem cell (CSC) resistance drivers. Life Sci. 2019;234:116781.
Not in our library10.1016/j.lfs.2019.116781
150.
Walker ND, et al. Exosomes from differentially activated macrophages influence dormancy or resurgence of breast cancer cells within bone marrow stroma. Cell Death Dis. 2019;10(2):59.
Not in our library10.1038/s41419-019-1304-z
151.
Bidirectional Crosstalk Between Cancer Stem Cells and Immune Cell Subsets · 2020
Not checked
152.
The role of stem cells in small-cell lung cancer: Evidence from chemoresistance to immunotherapy Seminars in Cancer Biology. 2022; 87160-169. 10.1016/j.semcancer.2022.11.006.
Not in our library10.1016/j.semcancer.2022.11.006
153.
Balaji S, et al. Emerging role of tumor microenvironment derived exosomes in therapeutic resistance and metastasis through epithelial-to-mesenchymal transition. Life Sci. 2021;280:119750.
Not in our library10.1016/j.lfs.2021.119750
154.
Luo S, et al. Macrophages Are a Double-Edged Sword: Molecular Crosstalk between Tumor-Associated Macrophages and Cancer Stem Cells. Biomolecules. 2022;12(6):850.
Not in our library10.3390/biom12060850
155.
Park SY, et al. Interleukin-8 is related to poor chemotherapeutic response and tumourigenicity in hepatocellular carcinoma. Eur J Cancer. 2014;50(2):341-350.
Not in our library10.1016/j.ejca.2013.09.021
156.
Cancer Stem Cells: Emerging Key Players in Immune Evasion of Cancers · 2021
Not checked
157.
Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors · 2020
No notice
158.
Dianat-Moghadam H, et al. Immune evader cancer stem cells direct the perspective approaches to cancer immunotherapy. Stem Cell Res Ther. 2022;13(1):1-12.
Not in our library10.1186/s13287-022-02829-9
159.
Cancer Stem Cells: Emerging Key Players in Immune Evasion of Cancers · 2021
Not checked
160.
Lee TKW, et al. Blockade of CD47-mediated cathepsin S/protease-activated receptor 2 signaling provides a therapeutic target for hepatocellular carcinoma. Hepatology. 2014;60(1):179-191.
Not in our library10.1002/hep.27070
161.
Nigro A, et al. Enhanced expression of CD47 is associated with off-target resistance to tyrosine kinase inhibitor gefitinib in NSCLC. Front Immunol. 2020;10:3135.
Not in our library10.3389/fimmu.2019.03135
162.
Induction of tolerogenic dendritic cells by activated TGF-β/Akt/Smad2 signaling in RIG-I-deficient stemness-high human liver cancer cells · 2019
Not checked
163.
Ma Y, et al. Dendritic cells in the cancer microenvironment. J Cancer. 2013;4(1):36.
Not in our library10.7150/jca.5046
164.
Ravindran S, Rasool S, Maccalli CJCM. The cross talk between cancer stem cells/cancer initiating cells and tumor microenvironment: the missing piece of the puzzle for the efficient targeting of these cells with immunotherapy. Cancer Microenviron. 2019;12(2):133-148.
Not in our library10.1007/s12307-019-00233-1
165.
Dianat-Moghadam H, Sharifi M, Salehi R, Keshavarz M, Shahgolzari M, Amoozgar Z. Engaging stemness improves cancer immunotherapy. Cancer Lett. 2023;554:216007. 10.1016/j.canlet.2022.216007.
Not in our library10.1016/j.canlet.2022.216007
166.
Solis-Castillo LA, et al. Tumor-infiltrating regulatory T cells, CD8/Treg ratio, and cancer stem cells are correlated with lymph node metastasis in patients with early breast cancer. Breast Cancer. 2020;27(5):837-849.
Not in our library10.1007/s12282-020-01079-y
167.
Komura N, et al. The role of myeloid-derived suppressor cells in increasing cancer stem-like cells and promoting PD-L1 expression in epithelial ovarian cancer. Cancer Immunol Immunother. 2020;69(12):2477-2499.
Not in our library10.1007/s00262-020-02628-2
168.
Tomić S, et al. Prostaglanin-E2 potentiates the suppressive functions of human mononuclear myeloid-derived suppressor cells and increases their capacity to expand IL-10-producing regulatory T cell subsets. Front Immunol. 2019;10:475.
Not in our library10.3389/fimmu.2019.00475
169.
Cross-talk between cancer stem cells and immune cells: potential therapeutic targets in the tumor immune microenvironment · 2023
No notice
170.
Hypoxia inducible factor HIF-1 promotes myeloid-derived suppressor cells accumulation through ENTPD2/CD39L1 in hepatocellular carcinoma · 2017
No notice
171.
Xu M, et al. Interactions between interleukin-6 and myeloid-derived suppressor cells drive the chemoresistant phenotype of hepatocellular cancer. Exp Cell Res. 2017;351(2):142-149.
Not in our library10.1016/j.yexcr.2017.01.008
172.
Gardner RA, et al. Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Exp Cell Res. 2017;129(25):3322-3331.
Not in our library10.1182/blood-2017-02-769208
173.
Maude SL, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439-448.
Not in our library10.1056/nejmoa1709866
174.
Fry TJ, et al. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat Med. 2018;24(1):20-28.
Not in our library10.1038/nm.4441
175.
Lee DW, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015;385(9967):517-528.
Not in our library10.1016/s0140-6736(14)61403-3
176.
CAR-T cell combination therapy: the next revolution in cancer treatment · 2022
No notice
177.
Bozorgi A, Bozorgi M, Khazaei M. Immunotherapy and immunoengineering for breast cancer; a comprehensive insight into CAR-T cell therapy advancements, challenges and prospects. Cell Oncol (Dordr). 2022;45(5):755-777.
Not in our library10.1007/s13402-022-00700-w
178.
CAR-T cell therapy: current limitations and potential strategies · 2021
No notice
179.
Current approaches to increase CAR T cell potency in solid tumors: targeting the tumor microenvironment · 2017
No notice
180.
Targeting Epithelial–Mesenchymal Transition (EMT) to Overcome Drug Resistance in Cancer · 2016
No notice
181.
Ribatti D, Tamma R, Annese T. Epithelial-mesenchymal transition in cancer: a historical overview. Transl Oncol. 2020;13(6):100773.
Not in our library10.1016/j.tranon.2020.100773
182.
Guidelines and definitions for research on epithelial–mesenchymal transition · 2020
Corrected
183.
Pyruvate Dehydrogenase Contributes to Drug Resistance of Lung Cancer Cells Through Epithelial Mesenchymal Transition · 2022
Not checked
184.
Das V, et al. The basics of epithelial–mesenchymal transition (EMT): A study from a structure, dynamics, and functional perspective. J Cell Physiol. 2019;234(9):14535-14555.
Not in our library10.1002/jcp.28160
185.
Lu J, et al. ZEB1: catalyst of immune escape during tumor metastasis. Biomed Pharmacother. 2022;153:113490.
Not in our library10.1016/j.biopha.2022.113490
186.
Funato N, Yanagisawa H. TBX1 targets the miR-200–ZEB2 axis to induce epithelial differentiation and inhibit stem cell properties. Sci Rep. 2022;12(1):20188.
Not in our library10.1038/s41598-022-24604-9
187.
Bencivenga M, Decimo I, Malpeli G. A therapeutic perspective for proliferative vitreoretinopathy based on the inhibition of epithelial-mesenchymal transition by miR-194. Ann Transl Med. 2020;8(8):525.
Not in our library10.21037/atm.2020.03.181
188.
Title AC, et al. The miR-200–Zeb1 axis regulates key aspects of β-cell function and survival in vivo. Mol Metab. 2021;53:101267.
Not in our library10.1016/j.molmet.2021.101267
189.
Dai Y, et al. Copy number gain of ZEB1 mediates a double-negative feedback loop with miR-33a-5p that regulates EMT and bone metastasis of prostate cancer dependent on TGF-β signaling. Theranostics. 2019;9(21):6063.
Not in our library10.7150/thno.36735
190.
Heterogeneity and plasticity of epithelial–mesenchymal transition (EMT) in cancer metastasis: Focusing on partial EMT and regulatory mechanisms · 2023
No notice
191.
ZEB1‐associated drug resistance in cancer cells is reversed by the class I HDAC inhibitor mocetinostat · 2015
No notice
192.
Zhang X, et al. ZEB1 confers chemotherapeutic resistance to breast cancer by activating ATM. Cell Death Dis. 2018;9(2):1-15.
Not in our library10.1038/s41419-017-0087-3
193.
Xie SL, et al. SOX8 regulates cancer stem-like properties and cisplatin-induced EMT in tongue squamous cell carcinoma by acting on the Wnt/β-catenin pathway. Int J Cancer. 2018;142(6):1252-1265.
Not in our library10.1002/ijc.31134
194.
Liang Y, et al. Epigenetic activation of TWIST1 by MTDH promotes cancer stem–like cell traits in breast cancer. Cancer Res. 2015;75(17):3672-3680.
Not in our library10.1158/0008-5472.can-15-0930
195.
Modulation of SOX2 expression delineates an end-point for paclitaxel-effectiveness in breast cancer stem cells · 2017
Not checked
196.
Li Q, et al. Subcellular drug distribution: mechanisms and roles in drug efficacy, toxicity, resistance, and targeted delivery. Drug Metab Rev. 2018;50(4):430-447.
Not in our library10.1080/03602532.2018.1512614
197.
Sakhrani NM, Padh H. Organelle targeting: third level of drug targeting. Drug Des Devel Ther. 2013;7:585.
Not in our library10.2147/dddt.s45614
198.
Boedtkjer E, Pedersen SF. The acidic tumor microenvironment as a driver of cancer. Annu Rev Physiol. 2020;82:103-126.
Not in our library10.1146/annurev-physiol-021119-034627
199.
Audero MM, Prevarskaya N, Pla A. F, Ca2+ Signalling and Hypoxia/Acidic Tumour Microenvironment Interplay in Tumour Progression. Int J Mol Sci. 2022;23(13):7377.
Not in our library10.3390/ijms23137377
200.
Goswami KK, et al. Lactic acid in alternative polarization and function of macrophages in tumor microenvironment. Hum Immunol. 2022;83(5):409-417.
Not in our library10.1016/j.humimm.2022.02.007
201.
Acidic extracellular microenvironment and cancer · 2013
No notice
202.
Pilon-Thomas S, et al. Neutralization of tumor acidity improves antitumor responses to immunotherapy. Cancer Res. 2016;76(6):1381-1390.
Not in our library10.1158/0008-5472.can-15-1743
203.
Guo Y, et al. Mechanisms of chemotherapeutic resistance and the application of targeted nanoparticles for enhanced chemotherapy in colorectal cancer. J Nanobiotechnology. 2022;20(1):1-24.
Not in our library10.1186/s12951-022-01586-4
204.
Dhar G, Sen S, Chaudhuri G. Acid Gradient Across Plasma Membrane can Drive Phosphate-Bond Synthesis in Cancer Cells: Acidic Tumor Milieu can Act as a Potential Energy Source. PLoS ONE. 2015;29:725.28.
Not in our library10.1371/journal.pone.0124070
205.
Dhar G, Sen S, Chaudhuri GJPO. Acid gradient across plasma membrane can drive phosphate bond synthesis in cancer cells: acidic tumor milieu as a potential energy source. PLoS ONE. 2015;10(4):e0124070.
Not in our library10.1371/journal.pone.0124070
206.
Halcrow PW, et al. Overcoming chemoresistance: Altering pH of cellular compartments by chloroquine and hydroxychloroquine. Front Cell Dev Biol. 2021;9:627639.
Not in our library10.3389/fcell.2021.627639
207.
Lactate in the Tumor Microenvironment: An Essential Molecule in Cancer Progression and Treatment · 2020
No notice
208.
Xiang Y-L, et al. Zwitterionic meso-silica/polypeptide hybrid nanoparticles for efficient azithromycin delivery and photodynamic therapy for synergistic treatment of drug-resistant bacterial infection. Int J Biol Macromol. 2022;219:597-610.
Not in our library10.1016/j.ijbiomac.2022.08.022
209.
Hulikova A. Swietach P, Nuclear proton dynamics and interactions with calcium signaling. J Mol Cell Cardiol. 2016;96:26-37.
Not in our library10.1016/j.yjmcc.2015.07.003
210.
Ji X, et al. Chemoresistance mechanisms of breast cancer and their countermeasures. Biomed Pharmacother. 2019;114:108800.
Not in our library10.1016/j.biopha.2019.108800
211.
Yuan D, et al. Interruption of endolysosomal trafficking leads to stroke brain injury. Exp Neurol. 2021;345:113827.
Not in our library10.1016/j.expneurol.2021.113827
212.
Exosomes induce endolysosomal permeabilization as a gateway by which exosomal tau seeds escape into the cytosol · 2021
No notice
213.
McGuire C, et al. Regulation of V-ATPase activity. Front Biosci (Landmark Ed). 2017;22(4):609-622.
Not in our library10.2741/4506
214.
Webb BA, et al. pHLARE: a new biosensor reveals decreased lysosome pH in cancer cells. Mol Biol Cell. 2021;32(2):131-142.
Not in our library10.1091/mbc.e20-06-0383
215.
The role of lysosomes in cancer development and progression · 2020
No notice
216.
Zhitomirsky B, Assaraf RK. Lysosomes as mediators of drug resistance in cancer. Drug Resist Updat. 2016;24:23-33.
Not in our library10.1016/j.drup.2015.11.004
217.
Geisslinger F, et al. Targeting lysosomes in cancer as promising strategy to overcome chemoresistance—a mini review. Front Oncol. 2020;10:1156.
Not in our library10.3389/fonc.2020.01156
218.
Hraběta J, et al. Drug sequestration in lysosomes as one of the mechanisms of chemoresistance of cancer cells and the possibilities of its inhibition. Int J Mol Sci. 2020;21(12):4392.
Not in our library10.3390/ijms21124392
219.
Al-Akra L, et al. Tumor stressors induce two mechanisms of intracellular P-glycoprotein–mediated resistance that are overcome by lysosomal-targeted thiosemicarbazones. J Biol Chem. 2018;293(10):3562-3587.
Not in our library10.1074/jbc.m116.772699
220.
Fu Z, et al. CQ sensitizes human pancreatic cancer cells to gemcitabine through the lysosomal apoptotic pathway via reactive oxygen species. Mol Oncol. 2018;12(4):529-544.
Not in our library10.1002/1878-0261.12179
221.
Sharapova TN, et al. FasL on the surface of Tag7 (PGRP-S)-activated lymphocytes induces necroptosis in HLA-negative tumor cells with the involvement of lysosomes and mitochondria. Biochimie. 2018;152:174-180.
Not in our library10.1016/j.biochi.2018.07.003
222.
Seebacher NA, et al. A mechanism for overcoming P-glycoprotein-mediated drug resistance: novel combination therapy that releases stored doxorubicin from lysosomes via lysosomal permeabilization using Dp44mT or DpC. Cell Death Dis. 2016;7(12):e2510-e2510.
Not in our library10.1038/cddis.2016.381
223.
Salaroglio IC, et al. Increasing intratumor C/EBP-β LIP and nitric oxide levels overcome resistance to doxorubicin in triple negative breast cancer. J Exp Clin Cancer Res. 2018;37(1):1-20.
Not in our library10.1186/s13046-018-0967-0
224.
Champagne DP, et al. Fine-tuning of CD8+ T cell mitochondrial metabolism by the respiratory chain repressor MCJ dictates protection to influenza virus. Immunity. 2016;44(6):1299-1311.
Not in our library10.1016/j.immuni.2016.02.018
225.
Barbier-Torres L, et al. The mitochondrial negative regulator MCJ is a therapeutic target for acetaminophen-induced liver injury. Nat Commun. 2017;8(1):1-11.
Not in our library10.1038/s41467-017-01970-x
226.
Hatle KM, et al. MCJ/DnaJC15, an endogenous mitochondrial repressor of the respiratory chain that controls metabolic alterations. Mol Cell Biol. 2013;33(11):2302-2314.
Not in our library10.1128/mcb.00189-13
227.
Mitochondrial ATP fuels ABC transporter-mediated drug efflux in cancer chemoresistance · 2021
No notice
228.
Miglietta S. Deciphering the role of the mitochondrial chaperonine MCJ in ovarian cancer. 2021.
Not in our library
229.
Cytoplasmic vacuolization in cell death and survival · 2016
No notice
230.
Lin H, et al. Overcoming Taxol-resistance in A549 cells: A comprehensive strategy of targeting P-gp transporter, AKT/ERK pathways, and cytochrome P450 enzyme CYP1B1 by 4-hydroxyemodin. Biochem Pharmacol. 2020;171:113733.
Not in our library10.1016/j.bcp.2019.113733
231.
Belisario DC, et al. Hypoxia dictates metabolic rewiring of tumors: implications for chemoresistance. Cells. 2020;9(12):2598.
Not in our library10.3390/cells9122598
232.
Liang W, et al. Role of reactive oxygen species in tumors based on the ‘seed and soil’theory: A complex interaction. Oncol Rep. 2021;46(3):1-15.
Not in our library10.3892/or.2021.8159
233.
Pascual-Ahuir A, Manzanares-Estreder S, Proft M. Pro- and Antioxidant Functions of the Peroxisome-Mitochondria Connection and Its Impact on Aging and Disease. Oxid Med Cell Longev. 2017;2017:9860841. 10.1155/2017/9860841.
Not in our library10.1155/2017/9860841
234.
Jacqueroux E, et al. Value of quantifying ABC transporters by mass spectrometry and impact on in vitro-to-in vivo prediction of transporter-mediated drug-drug interactions of rivaroxaban. Eur J Pharm Biopharm. 2020;148:27-37.
Not in our library10.1016/j.ejpb.2020.01.002
235.
Dang Y, et al. P-Gp and TOPO II Expression and Their Clinical Significance in Colon Cancer. Ann Clin Lab Sci. 2020;50(5):584-590.
Not in our library
236.
Heming CP, et al. P-glycoprotein and cancer: what do we currently know? 2022.
Not in our library10.1016/j.heliyon.2022.e11171
237.
Mirzaei S, Gholami MH, Hashemi F, Zabolian A, Farahani MV, Hushmandi K, Zarrabi A, Goldman A, Ashrafizadeh M, Orive G. Advances in understanding the role of P-gp in doxorubicin resistance: Molecular pathways, therapeutic strategies, and prospects. Drug Discov Today. 2022;27(2):436-455.
Not in our library10.1016/j.drudis.2021.09.020
238.
Aspects of the Tumor Microenvironment Involved in Immune Resistance and Drug Resistance · 2021
No notice
239.
Targeting the tumor stroma for cancer therapy · 2022
No notice
240.
Concepts of extracellular matrix remodelling in tumour progression and metastasis · 2020
No notice
241.
CAFs secreted exosomes promote metastasis and chemotherapy resistance by enhancing cell stemness and epithelial-mesenchymal transition in colorectal cancer · 2019
No notice
242.
Jena BC, et al. Cancer associated fibroblast mediated chemoresistance: A paradigm shift in understanding the mechanism of tumor progression. Biochim Biophys Acta Rev Cancer. 2020;1874(2):188416.
Not in our library10.1016/j.bbcan.2020.188416
243.
Haider T, et al. Drug resistance in cancer: mechanisms and tackling strategies. Pharmacol Rep. 2020;72(5):1125-1151.
Not in our library10.1007/s43440-020-00138-7
244.
Guo Z, Ashrafizadeh M, Zhang W, Zou R, Sethi G, Zhang X. Molecular profile of metastasis, cell plasticity and EMT in pancreatic cancer: a pre-clinical connection to aggressiveness and drug resistance. Cancer Metastasis Rev. 2023. 10.1007/s10555-023-10125-y.
Not in our library10.1007/s10555-023-10125-y
245.
Che Y, et al. Cisplatin-activated PAI-1 secretion in the cancer-associated fibroblasts with paracrine effects promoting esophageal squamous cell carcinoma progression and causing chemoresistance. Cell Death Dis. 2018;9(7):1-13.
Not in our library10.1038/s41419-018-0808-2
246.
Luraghi P, et al. MET Signaling in Colon Cancer Stem-like Cells Blunts the Therapeutic Response to EGFR InhibitorsMET in Colon Cancer-Initiating Cells. Can Res. 2014;74(6):1857-1869.
Not in our library10.1158/0008-5472.can-13-2340-t
247.
Cancer-associated fibroblasts as abettors of tumor progression at the crossroads of EMT and therapy resistance · 2019
No notice
248.
Hamidi H, Ivaska J. Every step of the way: integrins in cancer progression and metastasis. Nat Rev Cancer. 2018;18(9):533-548.
Not in our library10.1038/s41568-018-0038-z
249.
Fang Z, Meng Q, Xu J, Wang W, Zhang B, Liu J, Liang C, Hua J, Zhao Y, Yu X, Shi S. Signaling pathways in cancer-associated fibroblasts: recent advances and future perspectives. Cancer Commun (Lond). 2023;43(1):3-41.
Not in our library10.1002/cac2.12392
250.
Martino MM, et al. Growth factors engineered for super-affinity to the extracellular matrix enhance tissue healing. Science. 2014;343(6173):885-888.
Not in our library10.1126/science.1247663
251.
Role of Extracellular Matrix in Development and Cancer Progression · 2018
No notice
252.
Kaemmerer E, Loessner D, Avery VM. Addressing the tumour microenvironment in early drug discovery: a strategy to overcome drug resistance and identify novel targets for cancer therapy. Drug Discov Today. 2021;26(3):663-676.
Not in our library10.1016/j.drudis.2020.11.030
253.
Teng PN, et al. Identification of candidate circulating cisplatin-resistant biomarkers from epithelial ovarian carcinoma cell secretomes. Br J Cancer. 2014;110(1):123-132.
Not in our library10.1038/bjc.2013.687
254.
Wu Y-H, et al. COL11A1 confers chemoresistance on ovarian cancer cells through the activation of Akt/c/EBPβ pathway and PDK1 stabilization. Oncotarget. 2015;6(27):23748.
Not in our library10.18632/oncotarget.4250
255.
Cooper J, Giancotti FG. Integrin Signaling in Cancer: Mechanotransduction, Stemness, Epithelial Plasticity, and Therapeutic Resistance. Cancer Cell. 2019;35(3):347-367.
Not in our library10.1016/j.ccell.2019.01.007
256.
Targeting focal adhesion kinase in cancer cells and the tumor microenvironment · 2020
No notice
257.
Senthebane DA, et al. The role of tumor microenvironment in chemoresistance: 3D extracellular matrices as accomplices. Int J Mol Sci. 2018;19(10):2861.
Not in our library10.3390/ijms19102861
258.
Hong Y, Rao Y. Current status of nanoscale drug delivery systems for colorectal cancer liver metastasis. Biomed Pharmacother. 2019;114:108764. 10.1016/j.biopha.2019.108764.
Not in our library10.1016/j.biopha.2019.108764
259.
Exosomes: composition, biogenesis, and mechanisms in cancer metastasis and drug resistance · 2019
No notice
260.
Exosome-mediated metabolic reprogramming: the emerging role in tumor microenvironment remodeling and its influence on cancer progression · 2020
No notice
261.
Dianat-Moghadam H, et al. The role of circulating tumor cells in the metastatic cascade: biology, technical challenges, and clinical relevance. Cancers. 2020;12(4):867.
Not in our library10.3390/cancers12040867
262.
Li S, Yi M, Dong B, Jiao Y, Luo S, Wu K. The roles of exosomes in cancer drug resistance and its therapeutic application. Clin Transl Med. 2020;10(8):e257. 10.1002/ctm2.257.
Not in our library10.1002/ctm2.257
263.
Therapy resistance mediated by exosomes · 2019
No notice
264.
Ji R, et al. Exosomes derived from human mesenchymal stem cells confer drug resistance in gastric cancer. Cell Cycle. 2015;14(15):2473-2483.
Not in our library10.1080/15384101.2015.1005530
265.
Lukanović D, et al. The contribution of copper efflux transporters ATP7A and ATP7B to chemoresistance and personalized medicine in ovarian cancer. Biomed Pharmacother. 2020;129:110401.
Not in our library10.1016/j.biopha.2020.110401
266.
Zaidi M, et al. Quantitative visualization of hypoxia and proliferation gradients within histological tissue sections. Front Bioeng Biotechnol. 2019;7:397.
Not in our library10.3389/fbioe.2019.00397
267.
Overexpression of hypoxia-inducible factor and metabolic pathways: possible targets of cancer · 2017
No notice
268.
Warfel NA, El-Deiry WS. HIF-1 signaling in drug resistance to chemotherapy. Curr Med Chem. 2014;21(26):3021-3028.
Not in our library10.2174/0929867321666140414101056
269.
Xia Y, Jiang L, Zhong T. The role of HIF-1α in chemo-/radioresistant tumors. Onco Targets Ther. 2018;11:3003.
Not in our library10.2147/ott.s158206
270.
Nishimoto A, et al. HIF-1α activation under glucose deprivation plays a central role in the acquisition of anti-apoptosis in human colon cancer cells. Int J Oncol. 2014;44(6):2077-2084.
Not in our library10.3892/ijo.2014.2367
271.
Zhao Q, et al. Enhancement of drug sensitivity by knockdown of HIF-1α in gastric carcinoma cells. Oncol Res. 2016;23(3):129.
Not in our library10.3727/096504015x14500513118029
272.
Chen W-L, et al. Cycling hypoxia induces chemoresistance through the activation of reactive oxygen species-mediated B-cell lymphoma extra-long pathway in glioblastoma multiforme. J Transl Med. 2015;13(1):1-13.
Not in our library10.1186/s12967-015-0758-8
273.
Shaping Polarization Of Tumor-Associated Macrophages In Cancer Immunotherapy · 2022
No notice
274.
Lei X, et al. Immune cells within the tumor microenvironment: Biological functions and roles in cancer immunotherapy. Cancer Lett. 2020;470:126-133.
Not in our library10.1016/j.canlet.2019.11.009
275.
Larionova I, et al. Interaction of tumor-associated macrophages and cancer chemotherapy. Oncoimmunology. 2019;8(7):e1596004.
Not in our library10.1080/2162402x.2019.1596004
276.
Liu Y, Cao X. The origin and function of tumor-associated macrophages. Cell Mol Immunol. 2015;12(1):1-4.
Not in our library10.1038/cmi.2014.83
277.
Moradi-Chaleshtori M, et al. In vitro and in vivo evaluation of anti-tumoral effect of M1 phenotype induction in macrophages by miR-130 and miR-33 containing exosomes. Cancer Immunol Immunother. 2021;70(5):1323-1339.
Not in our library10.1007/s00262-020-02762-x
278.
Yu S, et al. Activated HIF1α of tumor cells promotes chemoresistance development via recruiting GDF15-producing tumor-associated macrophages in gastric cancer. Cancer Immunol Immunother. 2020;69(10):1973-1987.
Not in our library10.1007/s00262-020-02598-5
279.
Incio J, et al. Obesity-Induced Inflammation and Desmoplasia Promote Pancreatic Cancer Progression and Resistance to Chemotherapy. Cancer Discov. 2016;6(8):852-869.
Not in our library10.1158/2159-8290.cd-15-1177
280.
Targeting and exploitation of tumor-associated neutrophils to enhance immunotherapy and drug delivery for cancer treatment · 2020
Not checked
281.
Pylaeva E, Lang S, Jablonska J. The essential role of type I interferons in differentiation and activation of tumor-associated neutrophils. Front Immunol. 2016;7:629.
Not in our library10.3389/fimmu.2016.00629
282.
Liu X-D, et al. Resistance to Antiangiogenic Therapy Is Associated with an Immunosuppressive Tumor Microenvironment in Metastatic Renal Cell CarcinomaAntiangiogenic Therapy Increases PD-L1 Expression. Cancer Immunol Res. 2015;3(9):1017-1029.
Not in our library10.1158/2326-6066.cir-14-0244
283.
Colorectal cancer cell-derived CCL20 recruits regulatory T cells to promote chemoresistance via FOXO1/CEBPB/NF-κB signaling · 2019
Corrected
284.
Long Y, et al. Dysregulation of Glutamate Transport Enhances Treg Function That Promotes VEGF Blockade Resistance in Glioblastoma. Cancer Res. 2020;80(3):499-509.
Not in our library10.1158/0008-5472.can-19-1577
285.
Metabolic Plasticity in Chemotherapy Resistance · 2020
No notice
286.
Ragni M, et al. Amino acids in cancer and cachexia: An integrated view. Cancers (Basel). 2022;14(22):5691.
Not in our library10.3390/cancers14225691
287.
Cancer metabolic reprogramming: importance, main features, and potentials for precise targeted anti-cancer therapies. · 2014
No notice
288.
Effects of altered glycolysis levels on CD8+ T cell activation and function · 2023
No notice
289.
Khodaei T, et al. Drug delivery for metabolism targeted cancer immunotherapy. Adv Drug Deliv Rev. 2022;184:114242.
Not in our library10.1016/j.addr.2022.114242
290.
MCT4 Defines a Glycolytic Subtype of Pancreatic Cancer with Poor Prognosis and Unique Metabolic Dependencies · 2014
Not checked
291.
Ruprecht B, et al. Lapatinib resistance in breast cancer cells is accompanied by phosphorylation-mediated reprogramming of glycolysis. Cancer Res. 2017;77(8):1842-1853.
Not in our library10.1158/0008-5472.can-16-2976
292.
Zhang Y, et al. Targeting Glucose Metabolism Enzymes in Cancer Treatment: Current and Emerging Strategies. Cancers (Basel). 2022;14(19):4568.
Not in our library10.3390/cancers14194568
293.
Up‐regulation of glycolysis promotes the stemness and EMT phenotypes in gemcitabine‐resistant pancreatic cancer cells · 2017
No notice
294.
Targeting Glucose Metabolism to Overcome Resistance to Anticancer Chemotherapy in Breast Cancer · 2020
No notice
295.
Krasnov GS, et al. Targeting VDAC-bound hexokinase II: a promising approach for concomitant anti-cancer therapy. Expert Opin Ther Targets. 2013;17(10):1221-1233.
Not in our library10.1517/14728222.2013.833607
296.
Boison D. Yegutkin G G, Adenosine metabolism: emerging concepts for cancer therapy. Cancer Cell. 2019;36(6):582-596.
Not in our library10.1016/j.ccell.2019.10.007
297.
Allard B, et al. The adenosine pathway in immuno-oncology. Nat Rev Clin Oncol. 2020;17(10):611-629.
Not in our library10.1038/s41571-020-0382-2
298.
Sade-Feldman M, et al. Defining T cell states associated with response to checkpoint immunotherapy in melanoma. Cell. 2019;176(1):404.
Not in our library10.1016/j.cell.2018.12.034
299.
Song Y, et al. Drug-metabolizing cytochrome P450 enzymes have multifarious influences on treatment outcomes. Clin Pharmacokinet. 2021;60:585-601.
Not in our library10.1007/s40262-021-01001-5
300.
Parashar A, Manoj K. Murburn precepts for cytochrome P450 mediated drug/xenobiotic metabolism and homeostasis. Curr Drug Metab. 2021;22(4):315-326.
Not in our library10.2174/18755453mtezwmzuk5
301.
Vredenburg G, den Braver-Sewradj S, van Vugt-Lussenburg BM, Vermeulen NP, Commandeur JN, Vos JC. Activation of the anticancer drugs cyclophosphamide and ifosfamide by cytochrome P450 BM3 mutants. Toxicol Lett. 2015;232(1):182-92.
Not in our library10.1016/j.toxlet.2014.11.005
302.
Voelcker, G. Enzyme catalyzed decomposition of 4-hydroxycyclophosphamide. in The Open Conference Proceedings Journal. 2017.
Not in our library
303.
Yang W, et al. Cyclophosphamide Exposure Causes Long-Term Detrimental Effect of Oocytes Developmental Competence Through Affecting the Epigenetic Modification and Maternal Factors’ Transcription During Oocyte Growth. Front Cell Dev Biol. 2021;9:682060.
Not in our library10.3389/fcell.2021.682060
304.
Bagdasaryan AA, et al. Pharmacogenetics of drug metabolism: the role of gene polymorphism in the regulation of doxorubicin safety and efficacy. Cancers (Basel). 2022;14(21):5436.
Not in our library10.3390/cancers14215436
305.
Mechanisms and insights into drug resistance in cancer · 2013
No notice
306.
Arwanih, E.Y., et al., Resistance mechanism of acute myeloid leukemia cells against daunorubicin and cytarabine: a literature review. 2022. 14(12).
Not in our library10.7759/cureus.33165
307.
Levin M, et al. Surmounting Cytarabine-resistance in acute myeloblastic leukemia cells and specimens with a synergistic combination of hydroxyurea and azidothymidine. Cell Death Dis. 2019;10(6):390.
Not in our library10.1038/s41419-019-1626-x
308.
Costea T, et al. Alleviation of multidrug resistance by flavonoid and non-flavonoid compounds in breast, lung, colorectal and prostate cancer. Int J Mol Sci. 2020;21(2):401.
Not in our library10.3390/ijms21020401
309.
Varela-López A, et al. An update on the mechanisms related to cell death and toxicity of doxorubicin and the protective role of nutrients. Food Chem Toxicol. 2019;134:110834.
Not in our library10.1016/j.fct.2019.110834
310.
Reprogramming of glutamine metabolism via glutamine synthetase silencing induces cisplatin resistance in A2780 ovarian cancer cells · 2021
Not checked
311.
Wang SF, Chang YL, Fang WL, Li AF, Chen CF, Yeh TS, Hung GY, Huang KH, Lee HC. Growth differentiation factor 15 induces cisplatin resistance through upregulation of xCT expression and glutathione synthesis in gastric cancer. Cancer Sci. 2023;114(8):3301-3317.
Not in our library10.1111/cas.15869
312.
Drug Resistance in Cancer: An Overview · 2014
No notice
313.
To C, et al. An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer. Nat Cancer. 2022;3(4):402-417.
Not in our library10.1038/s43018-022-00351-8
314.
Wu PS, Lin MH, Hsiao JC, Lin PY, Pan SH, Chen YJ. EGFR-T790M Mutation-Derived Interactome Rerouted EGFR Translocation Contributing to Gefitinib Resistance in Non-Small Cell Lung Cancer. Mol Cell Proteomics. 2023;22(9):100624. 10.1016/j.mcpro.2023.100624.
Not in our library10.1016/j.mcpro.2023.100624
315.
Chong CR, Jänne PA. The quest to overcome resistance to EGFR-targeted therapies in cancer. Nat Med. 2013;19(11):1389-1400.
Not in our library10.1038/nm.3388
316.
Schulte RR, Ho RH. Organic anion transporting polypeptides: emerging roles in cancer pharmacology. Mol Pharmacol. 2019;95(5):490-506.
Not in our library10.1124/mol.118.114314
317.
Brecht K, Schäfer AM, Meyer zu Schwabedissen HE. Uptake Transporters of the SLC21, SLC22A, and SLC15A Families in Anticancer Therapy—Modulators of Cellular Entry or Pharmacokinetics? Cancers (Basel). 2020;12(8):2263.
Not in our library10.3390/cancers12082263
318.
Klein I, et al. Glycyrrhizic Acid Prevents Paclitaxel-Induced Neuropathy via Inhibition of OATP-Mediated Neuronal Uptake. Cells. 2023;12(9):1249.
Not in our library10.3390/cells12091249
319.
Zhao D, Long X, Wang J. Transporter-mediated drug-drug interactions involving poly (ADP-ribose) polymerase inhibitors. Oncol Lett. 2023;25(4):1-8.
Not in our library10.3892/ol.2023.13747
320.
Drug-Drug Interactions at Organic Cation Transporter 1 · 2021
Not checked
321.
Lin L, Yee SW, Kim RB, Giacomini KM. SLC transporters as therapeutic targets: emerging opportunities. Nat Rev Drug Discov. 2015;14(8):543-60.
Not in our library10.1038/nrd4626
322.
Siemer S, et al. Profiling cisplatin resistance in head and neck cancer: A critical role of the VRAC ion channel for chemoresistance. Cancers (Basel). 2021;13(19):4831.
Not in our library10.3390/cancers13194831
323.
Cabral LKD, Tiribelli C, Sukowati CHJC. Sorafenib resistance in hepatocellular carcinoma: the relevance of genetic heterogeneity. Cancers (Basel). 2020;12(6):1576.
Not in our library10.3390/cancers12061576
324.
Otter M, et al. Expression and functional contribution of different organic cation transporters to the cellular uptake of doxorubicin into human breast cancer and cardiac tissue. Int J Mol Sci. 2021;23(1):255.
Not in our library10.3390/ijms23010255
325.
Edemir B. Identification of Prognostic Organic Cation and Anion Transporters in Different Cancer Entities by In Silico Analysis. Int J Mol Sci. 2020;21(12):4491.
Not in our library10.3390/ijms21124491
326.
Marin JJ, et al. The role of reduced intracellular concentrations of active drugs in the lack of response to anticancer chemotherapy. Acta Pharmacol Sin. 2014;35(1):1-10.
Not in our library10.1038/aps.2013.131
327.
Ortiz M, et al. Mechanisms of chemotherapy resistance in ovarian cancer. Cancer Drug Resist. 2022;5(2):304.
Not in our library10.20517/cdr.2021.147
328.
Arnesano F, Natile G. Interference between copper transport systems and platinum drugs. Semin Cancer Biol. 2021;76:173-188.
Not in our library10.1016/j.semcancer.2021.05.023
329.
De Luca A, et al. Copper homeostasis as target of both consolidated and innovative strategies of anti-tumor therapy. J Trace Elem Med Biol. 2019;55:204-213.
Not in our library10.1016/j.jtemb.2019.06.008
330.
Shiqun, Shao Jingxing, Si Youqing, Shen. Copper as the Target for Anticancer Nanomedicine. Abstr Adv Ther. 2019;2(5):10.1002/adtp.v2.5. 10.1002/adtp.201800147.
Not in our library
331.
Mohammad IS, et al. Understanding of human ATP binding cassette superfamily and novel multidrug resistance modulators to overcome MDR. Biomed Pharmacother. 2018;100:335-348.
Not in our library10.1016/j.biopha.2018.02.038
332.
Wu Z-X, et al. Elevated ABCB1 expression confers acquired resistance to aurora kinase inhibitor GSK-1070916 in cancer cells. Front Pharmacol. 2021;11:615824.
Not in our library10.3389/fphar.2020.615824
333.
Martins-Gomes C, Silva AM. Natural Products as a Tool to Modulate the Activity and Expression of Multidrug Resistance Proteins of Intestinal Barrier. J Xenobiot. 2023;13(2):172-192.
Not in our library10.3390/jox13020014
334.
Barnett-Griness O, Rennert G, Lejbkowicz F, Pinchev M, Saliba W, Gronich N. Association Between ABCG2, ABCB1, ABCC2 Efflux Transporter Single-Nucleotide Variants and Irinotecan Adverse Effects in Patients With Colorectal Cancer: A Real-Life Study. Clin Pharmacol Ther. 2023;113(3):704-711.
Not in our library10.1002/cpt.2833
335.
Petruzzelli R, Polishchuk RSJC. Activity and trafficking of copper-transporting ATPases in tumor development and defense against platinum-based drugs. Cells. 2019;8(9):1080.
Not in our library10.3390/cells8091080
336.
Zhang B, Burke R. Copper homeostasis and the ubiquitin proteasome system. Metallomics. 2023;15(3):mfad010.
Not in our library10.1093/mtomcs/mfad010
337.
Petruzzelli R, Polishchuk RS. Activity and Trafficking of Copper-Transporting ATPases in Tumor Development and Defense against Platinum-Based Drugs. Cells. 2019;8(9):1080.
Not in our library10.3390/cells8091080
338.
Zhang Z, et al. Reversing drug resistance of cisplatin by hsp90 inhibitors in human ovarian cancer cells. Int J Clin Exp Med. 2015;8(5):6687.
Not in our library
339.
Przystupski, D., et al., The modulatory effect of green tea catechin on drug resistance in human ovarian cancer cells. 2019. 28(5): 657-667.
Not in our library
340.
Hejmady S, Pradhan R, Alexander A, Agrawal M, Singhvi G, Gorain B, Tiwari S, Kesharwani P, Dubey SK. Recent advances in targeted nanomedicine as promising antitumor therapeutics. Drug Discov Today. 2020;25(12):2227-2244.
Not in our library10.1016/j.drudis.2020.09.031
341.
Autophagy and autophagy-related proteins in cancer · 2020
No notice
342.
Man SM, Jenkins BJ. Context-dependent functions of pattern recognition receptors in cancer. Nat Rev Cancer. 2022;22(7):397-413.
Not in our library10.1038/s41568-022-00462-5
343.
Manzoor S, et al. Autophagy: A versatile player in the progression of colorectal cancer and drug resistance. Nat Rev Cancer. 2022;12:924290.
Not in our library10.3389/fonc.2022.924290
344.
Marsh T, Debnath JJA. Autophagy suppresses breast cancer metastasis by degrading NBR1. Autophagy. 2020;16(6):1164-1165.
Not in our library10.1080/15548627.2020.1753001
345.
Khan SU, Fatima K, Singh U, Singh PP, Malik F. Small molecule '4ab' induced autophagy and endoplasmic reticulum stress-mediated death of aggressive cancer cells grown under adherent and floating conditions. Med Oncol. 2023;40(4):121.
Not in our library10.1007/s12032-023-01963-5
346.
Assi M, Kimmelman AC. Impact of context-dependent autophagy states on tumor progression. Nat Cancer. 2023;4(5):596-607.
Not in our library10.1038/s43018-023-00546-7
347.
Dower CM, Wills CA, Frisch SM, Wang HG. Mechanisms and context underlying the role of autophagy in cancer metastasis. Autophagy. 2018;14(7):1110-1128.
Not in our library10.1080/15548627.2018.1450020
348.
White E. Autophagy and p53. Cold Spring Harb Perspect Med. 2016;6(4):a026120.
Not in our library10.1101/cshperspect.a026120
349.
Levy JMM, Towers CG, Thorburn A. Targeting autophagy in cancer. Nat Rev Cancer. 2017;17(9):528-542.
Not in our library10.1038/nrc.2017.53
350.
Rahman MA, et al. Recent Update and Drug Target in Molecular and Pharmacological Insights into Autophagy Modulation in Cancer Treatment and Future Progress. Cells. 2023;12(3):458.
Not in our library10.3390/cells12030458
351.
Anand SK, et al. Entrenching role of cell cycle checkpoints and autophagy for maintenance of genomic integrity. DNA Repair (Amst). 2020;86:102748.
Not in our library10.1016/j.dnarep.2019.102748
352.
Ueno S, Sudo T. Hirasawa A, ATM: Functions of ATM kinase and its relevance to hereditary tumors. Int J Mol Sci. 2022;23(1):523.
Not in our library10.3390/ijms23010523
353.
Zhang L-H, et al. Enhanced autophagy reveals vulnerability of P-gp mediated epirubicin resistance in triple negative breast cancer cells. Apoptosis. 2016;21(4):473-488.
Not in our library10.1007/s10495-016-1214-9
354.
Liu ZR, Song Y, Wan LH, Zhang YY, Zhou LM. Over-expression of miR-451a can enhance the sensitivity of breast cancer cells to tamoxifen by regulating 14–3-3ζ, estrogen receptor α, and autophagy. Life Sci. 2016;149:104-13.
Not in our library10.1016/j.lfs.2016.02.059
355.
Lee MH, Koh D, Na H, Ka NL, Kim S, Kim HJ, Hong S, Shin YK, Seong JK, Lee MO. MTA1 is a novel regulator of autophagy that induces tamoxifen resistance in breast cancer cells. Autophagy. 2018;14(5):812-824.
Not in our library10.1080/15548627.2017.1388476
356.
Liu W, et al. Targeting the WEE1 kinase strengthens the antitumor activity of imatinib via promoting KIT autophagic degradation in gastrointestinal stromal tumors. Gastric Cancer. 2020;23:39-51.
Not in our library10.1007/s10120-019-00977-1
357.
Liu T, et al. Combination of an autophagy inducer and an autophagy inhibitor: a smarter strategy emerging in cancer therapy. Front Pharmacol. 2020;11:408.
Not in our library10.3389/fphar.2020.00408
358.
Endoplasmic reticulum stress signaling and chemotherapy resistance in solid cancers · 2017
No notice
359.
Inhibiting IRE1α-endonuclease activity decreases tumor burden in a mouse model for hepatocellular carcinoma · 2020
Not checked
360.
Khaled J, Kopsida M, Lennernäs H, Heindryckx F. Drug Resistance and Endoplasmic Reticulum Stress in Hepatocellular Carcinoma. Cells. 2022;11(4):632.
Not in our library10.3390/cells11040632
361.
Hetz C, Zhang K, Kaufman RJ. Mechanisms, regulation and functions of the unfolded protein response. Nat. Rev. Mol. Cell Biol. 2020;21:421-438.
Not in our library10.1038/s41580-020-0250-z
362.
Khaled J, et al. Drug resistance and endoplasmic reticulum stress in hepatocellular carcinoma. Cells. 2022;11(4):632.
Not in our library10.3390/cells11040632
363.
Wang H, Mi K. Emerging roles of endoplasmic reticulum stress in the cellular plasticity of cancer cells. Front Oncol. 2023;13:1110881.
Not in our library10.3389/fonc.2023.1110881
364.
Zhang C, et al. HMGB1-induced aberrant autophagy contributes to insulin resistance in granulosa cells in PCOS. FASEB J. 2020;34(7):9563-9574.
Not in our library10.1096/fj.202000605rr
365.
Li J, Zhou W, Mao Q, Gao D, Xiong L, Hu X, Zheng Y, Xu X. HMGB1 Promotes Resistance to Doxorubicin in Human Hepatocellular Carcinoma Cells by Inducing Autophagy via the AMPK/mTOR Signaling Pathway. Front Oncol. 2021;11:739145. 10.3389/fonc.2021.739145.
Not in our library10.3389/fonc.2021.739145
366.
Yu G, Klionsky DJ. Life and Death Decisions—The Many Faces of Autophagy in Cell Survival and Cell Death. Biomolecules. 2022;12(7):866.
Not in our library10.3390/biom12070866
367.
Gupta R, et al. Autophagy and apoptosis cascade: which is more prominent in neuronal death? Cell Mol Life Sci. 2021;78(24):8001-8047.
Not in our library10.1007/s00018-021-04004-4
368.
Booth LA, Roberts JL, Dent P. The role of cell signaling in the crosstalk between autophagy and apoptosis in the regulation of tumor cell survival in response to sorafenib and neratinib. Semin Cancer Biol. 2020;66:129-139.
Not in our library10.1016/j.semcancer.2019.10.013
369.
Anjum J, Mitra S, Das R, Alam R, Mojumder A, Emran TB, Islam F, Rauf A, Hossain MJ, Aljohani ASM, Abdulmonem WA, Alsharif KF, Alzahrani KJ, Khan H. A renewed concept on the MAPK signaling pathway in cancers: Polyphenols as a choice of therapeutics. Pharmacol Res. 2022;184:106398. 10.1016/j.phrs.2022.106398.
Not in our library10.1016/j.phrs.2022.106398
370.
Zhu S, Cao L, Yu Y, Yang L, Yang M, Liu K, Huang J, Kang R, Livesey KM, Tang D. Inhibiting autophagy potentiates the anticancer activity of IFN1@/IFNα in chronic myeloid leukemia cells. Autophagy. 2013;9(3):317-27.
Not in our library10.4161/auto.22923
371.
Balvers RK, et al. ABT-888 enhances cytotoxic effects of temozolomide independent of MGMT status in serum free cultured glioma cells. J Transl Med. 2015;13(1):1-10.
Not in our library10.1186/s12967-015-0427-y
372.
Mechanisms of doxorubicin-induced drug resistance and drug resistant tumour growth in a murine breast tumour model · 2019
No notice
373.
Mei Y, et al. Overexpression of RSK4 reverses doxorubicin resistance in human breast cancer cells via PI3K/AKT signalling pathway. J Biochem. 2020;167(6):603-611.
Not in our library10.1093/jb/mvaa009
374.
Al-Malky HS, Al Harthi SE, Osman A-MM. Major obstacles to doxorubicin therapy: Cardiotoxicity and drug resistance. J Oncol Pharm Pract. 2020;26(2):434-444.
Not in our library10.1177/1078155219877931
375.
Ramani S, Park S. HSP27 role in cardioprotection by modulating chemotherapeutic doxorubicin-induced cell death. J Mol Med (Berl). 2021;99(6):771-784.
Not in our library10.1007/s00109-021-02048-4
376.
Panneerpandian P, Rao DB, Ganesan K. Calcium channel blockers lercanidipine and amlodipine inhibit YY1/ERK/TGF-β mediated transcription and sensitize the gastric cancer cells to doxorubicin. Toxicol In Vitro. 2021;74:105152.
Not in our library10.1016/j.tiv.2021.105152
377.
Kang X, et al. DUSP4 promotes doxorubicin resistance in gastric cancer through epithelial-mesenchymal transition. Oncotarget. 2017;8(55):94028.
Not in our library10.18632/oncotarget.21522
378.
Lee H-J, Choi C-H. Characterization of SN38-resistant T47D breast cancer cell sublines overexpressing BCRP, MRP1, MRP2, MRP3, and MRP4. BMC Cancer. 2022;22(1):446.
Not in our library10.1186/s12885-022-09446-y
379.
Cho CJ, et al. The modulation study of multiple drug resistance in bladder cancer by curcumin and resveratrol. Oncol Lett. 2019;18(6):6869-6876.
Not in our library10.3892/ol.2019.11023
380.
Gupta SK, Singh P, Ali V, Verma M. Role of membrane-embedded drug efflux ABC transporters in the cancer chemotherapy. Oncol Rev. 2020;14(2):448.
Not in our library10.4081/oncol.2020
381.
Chemotherapy-induced complement signaling modulates immunosuppression and metastatic relapse in breast cancer · 2022
No notice
382.
Makovec T. Cisplatin and beyond: molecular mechanisms of action and drug resistance development in cancer chemotherapy. Radiol Oncol. 2019;53(2):148-158.
Not in our library10.2478/raon-2019-0018
383.
Bulathge AW, et al. Comparative cisplatin reactivity towards human Zn7-metallothionein-2 and MTF-1 zinc fingers: potential implications in anticancer drug resistance. Metallomics. 2022;14(9):mfac061.
Not in our library10.1093/mtomcs/mfac061
384.
Lee IT-L, et al. Cancer-Derived Extracellular Vesicles as Biomarkers for Cutaneous Squamous Cell Carcinoma: A Systematic Review. Cancers (Basel). 2022;14(20):5098.
Not in our library10.3390/cancers14205098
385.
Horibe S, et al. Mitochondrial DNA mutations are involved in the acquisition of cisplatin resistance in human lung cancer A549 cells. Oncol Rep. 2022;47(2):1-12.
Not in our library10.3892/or.2021.8243
386.
Targeting Molecular Mechanisms Underlying Treatment Efficacy and Resistance in Osteosarcoma: A Review of Current and Future Strategies · 2020
No notice
387.
Paclitaxel Through the Ages of Anticancer Therapy: Exploring Its Role in Chemoresistance and Radiation Therapy · 2015
No notice
388.
Germain N, et al. Lipid metabolism and resistance to anticancer treatment. Biology (Basel). 2020;9(12):474.
Not in our library10.3390/biology9120474
389.
Zhang J, Yin D, Li H. hMSH2 expression is associated with paclitaxel resistance in ovarian carcinoma, and inhibition of hMSH2 expression in vitro restores paclitaxel sensitivity. Oncol Rep. 2014;32(5):2199-2206.
Not in our library10.3892/or.2014.3430
390.
Mir MA, Khan SU, Aisha S. Cell Cycle Dysregulation in Breast Cancer. Therapeutic potential of Cell Cycle Kinases in Breast Cancer. 2023;103-131.
Not in our library
391.
Lopes D, et al. α-Tubulin detyrosination links the suppression of MCAK activity with taxol cytotoxicity. J Cell Biol. 2022;222(2):e202205092.
Not in our library10.1083/jcb.202205092
392.
Comparetti, E.J., et al., Cancer cell membrane-derived nanoparticles improve the activity of gemcitabine and paclitaxel on pancreatic cancer cells and coordinate immunoregulatory properties on professional antigen-presenting cells. 2020. 1(6): p. 1775-1787.
Not in our library
393.
Mohiuddin M, Kasahara K. Paclitaxel impedes EGFR-mutated PC9 cell growth via reactive oxygen species-mediated DNA damage and EGFR/PI3K/AKT/mTOR signaling pathway suppression. Cancer Genomics Proteomics. 2021;18(5):645-659.
Not in our library10.21873/cgp.20287
394.
Indini A, et al. NAD/NAMPT and mTOR pathways in melanoma: Drivers of drug resistance and prospective therapeutic targets. Int J Mol Sci. 2022;23(17):9985.
Not in our library10.3390/ijms23179985
395.
Dogan E, et al. Cancer stem cells in tumor modeling: Challenges and future directions. Advanced Nanobiomed Res. 2021;1(11):2100017.
Not in our library10.1002/anbr.202100017
396.
Vasan N, Baselga J, Hyman DM. A view on drug resistance in cancer. Nature. 2019;575(7782):299-309.
Not in our library10.1038/s41586-019-1730-1
397.
Oshimori N, Guo Y, Taniguchi S. An emerging role for cellular crosstalk in the cancer stem cell niche. J Pathol. 2021;254(4):384-394.
Not in our library10.1002/path.5655
398.
Drug resistance and Cancer stem cells · 2021
No notice
399.
Batlle E, Clevers H. Cancer stem cells revisited. Nat Med. 2017;23(10):1124-1134.
Not in our library10.1038/nm.4409
400.
Mirzaei S, Gholami MH, Hashemi F, Zabolian A, Farahani MV, Hushmandi K, Zarrabi A, Goldman A, Ashrafizadeh M, Orive G. Advances in understanding the role of P-gp in doxorubicin resistance: Molecular pathways, therapeutic strategies, and prospects. Drug Discov Today. 2022;27(2):436-455.
Not in our library10.1016/j.drudis.2021.09.020

Cited by papers we hold 1

Invasion and metastasis in cancer: molecular insights and therapeutic targets · 2025
No notice

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.